What is the current valuation of the Panic Disorder Market?

The Panic Disorder Market was valued at 11.42 USD Billion in 2024. Read More

What is the projected market valuation for the Panic Disorder Market in 2035?

The Panic Disorder Market is projected to reach 30.32 USD Billion by 2035. Read More

What is the expected CAGR for the Panic Disorder Market during the forecast period 2025 - 2035?

The expected CAGR for the Panic Disorder Market is 9.28% from 2025 to 2035. Read More

Which companies are the key players in the Panic Disorder Market?

Key players in the Panic Disorder Market include Pfizer, Johnson & Johnson, Eli Lilly, AstraZeneca, and Bristol-Myers Squibb. Read More

How did the Medications segment perform in 2024?

The Medications segment was valued at 3.42 USD Billion in 2024 and is projected to grow to 8.32 USD Billion. Read More

What is the market size for Severe Panic Disorder in 2024?

The market size for Severe Panic Disorder was 4.58 USD Billion in 2024. Read More

How does the Panic Disorder Market segment by age group?

The market segments by age group include Children and Adolescents, Adults, and Older Adults, with Adults valued at 6.5 USD Billion in 2024. Read More

What is the projected growth for the Mild Panic Disorder segment?

The Mild Panic Disorder segment is expected to grow from 2.28 USD Billion in 2024 to 5.92 USD Billion. Read More

What comorbidities are associated with Panic Disorder in the market?

Comorbidities include Agoraphobia, Social Anxiety Disorder, Generalized Anxiety Disorder, and Depression, with Generalized Anxiety Disorder valued at 3.42 USD Billion in 2024. Read More

Panic Disorder Market

Q: What are the major treatment segments in the Panic Disorder Market?

Major treatment segments include Medications, Psychotherapy, Cognitive Behavioral Therapy (CBT), and Exposure and Response Prevention (ERP). Read More

ID: MRFR/HC/25963-HCR

100 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Panic Disorder Market Research Report: Size, Share, Trend Analysis By Treatment (Medications, Psychotherapy, Cognitive Behavioral Therapy (CBT), Exposure and Response Prevention (ERP), By Severity (Mild Panic Disorder, Moderate Panic Disorder, Severe Panic Disorder), By Comorbidities (Agoraphobia, Social Anxiety Disorder, Generalized Anxiety Disorder, Depression), By Age Group (Children and Adolescents, Adults, Older Adults) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Treatment (USD Billion) | |
  1. 4.1.1 Medications | |
  2. 4.1.2 Psychotherapy | |
  3. 4.1.3 Cognitive Behavioral Therapy (CBT) | |
  4. 4.1.4 Exposure and Response Prevention (ERP) |
2. 4.2 Healthcare, BY Severity (USD Billion) | |
  1. 4.2.1 Mild Panic Disorder | |
  2. 4.2.2 Moderate Panic Disorder | |
  3. 4.2.3 Severe Panic Disorder |
3. 4.3 Healthcare, BY Comorbidities (USD Billion) | |
  1. 4.3.1 Agoraphobia | |
  2. 4.3.2 Social Anxiety Disorder | |
  3. 4.3.3 Generalized Anxiety Disorder | |
  4. 4.3.4 Depression |
4. 4.4 Healthcare, BY Age Group (USD Billion) | |
  1. 4.4.1 Children and Adolescents | |
  2. 4.4.2 Adults | |
  3. 4.4.3 Older Adults |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Johnson & Johnson (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Eli Lilly (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 AstraZeneca (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Bristol-Myers Squibb (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Novartis (CH) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GSK (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Otsuka Pharmaceutical (JP) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TREATMENT |
7. 6.4 US MARKET ANALYSIS BY SEVERITY |
8. 6.5 US MARKET ANALYSIS BY COMORBIDITIES |
9. 6.6 US MARKET ANALYSIS BY AGE GROUP |
10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT |
11. 6.8 CANADA MARKET ANALYSIS BY SEVERITY |
12. 6.9 CANADA MARKET ANALYSIS BY COMORBIDITIES |
13. 6.10 CANADA MARKET ANALYSIS BY AGE GROUP |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT |
16. 6.13 GERMANY MARKET ANALYSIS BY SEVERITY |
17. 6.14 GERMANY MARKET ANALYSIS BY COMORBIDITIES |
18. 6.15 GERMANY MARKET ANALYSIS BY AGE GROUP |
19. 6.16 UK MARKET ANALYSIS BY TREATMENT |
20. 6.17 UK MARKET ANALYSIS BY SEVERITY |
21. 6.18 UK MARKET ANALYSIS BY COMORBIDITIES |
22. 6.19 UK MARKET ANALYSIS BY AGE GROUP |
23. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT |
24. 6.21 FRANCE MARKET ANALYSIS BY SEVERITY |
25. 6.22 FRANCE MARKET ANALYSIS BY COMORBIDITIES |
26. 6.23 FRANCE MARKET ANALYSIS BY AGE GROUP |
27. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT |
28. 6.25 RUSSIA MARKET ANALYSIS BY SEVERITY |
29. 6.26 RUSSIA MARKET ANALYSIS BY COMORBIDITIES |
30. 6.27 RUSSIA MARKET ANALYSIS BY AGE GROUP |
31. 6.28 ITALY MARKET ANALYSIS BY TREATMENT |
32. 6.29 ITALY MARKET ANALYSIS BY SEVERITY |
33. 6.30 ITALY MARKET ANALYSIS BY COMORBIDITIES |
34. 6.31 ITALY MARKET ANALYSIS BY AGE GROUP |
35. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT |
36. 6.33 SPAIN MARKET ANALYSIS BY SEVERITY |
37. 6.34 SPAIN MARKET ANALYSIS BY COMORBIDITIES |
38. 6.35 SPAIN MARKET ANALYSIS BY AGE GROUP |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY SEVERITY |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY COMORBIDITIES |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TREATMENT |
45. 6.42 CHINA MARKET ANALYSIS BY SEVERITY |
46. 6.43 CHINA MARKET ANALYSIS BY COMORBIDITIES |
47. 6.44 CHINA MARKET ANALYSIS BY AGE GROUP |
48. 6.45 INDIA MARKET ANALYSIS BY TREATMENT |
49. 6.46 INDIA MARKET ANALYSIS BY SEVERITY |
50. 6.47 INDIA MARKET ANALYSIS BY COMORBIDITIES |
51. 6.48 INDIA MARKET ANALYSIS BY AGE GROUP |
52. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT |
53. 6.50 JAPAN MARKET ANALYSIS BY SEVERITY |
54. 6.51 JAPAN MARKET ANALYSIS BY COMORBIDITIES |
55. 6.52 JAPAN MARKET ANALYSIS BY AGE GROUP |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY SEVERITY |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY COMORBIDITIES |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT |
61. 6.58 MALAYSIA MARKET ANALYSIS BY SEVERITY |
62. 6.59 MALAYSIA MARKET ANALYSIS BY COMORBIDITIES |
63. 6.60 MALAYSIA MARKET ANALYSIS BY AGE GROUP |
64. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT |
65. 6.62 THAILAND MARKET ANALYSIS BY SEVERITY |
66. 6.63 THAILAND MARKET ANALYSIS BY COMORBIDITIES |
67. 6.64 THAILAND MARKET ANALYSIS BY AGE GROUP |
68. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT |
69. 6.66 INDONESIA MARKET ANALYSIS BY SEVERITY |
70. 6.67 INDONESIA MARKET ANALYSIS BY COMORBIDITIES |
71. 6.68 INDONESIA MARKET ANALYSIS BY AGE GROUP |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT |
73. 6.70 REST OF APAC MARKET ANALYSIS BY SEVERITY |
74. 6.71 REST OF APAC MARKET ANALYSIS BY COMORBIDITIES |
75. 6.72 REST OF APAC MARKET ANALYSIS BY AGE GROUP |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT |
78. 6.75 BRAZIL MARKET ANALYSIS BY SEVERITY |
79. 6.76 BRAZIL MARKET ANALYSIS BY COMORBIDITIES |
80. 6.77 BRAZIL MARKET ANALYSIS BY AGE GROUP |
81. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT |
82. 6.79 MEXICO MARKET ANALYSIS BY SEVERITY |
83. 6.80 MEXICO MARKET ANALYSIS BY COMORBIDITIES |
84. 6.81 MEXICO MARKET ANALYSIS BY AGE GROUP |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT |
86. 6.83 ARGENTINA MARKET ANALYSIS BY SEVERITY |
87. 6.84 ARGENTINA MARKET ANALYSIS BY COMORBIDITIES |
88. 6.85 ARGENTINA MARKET ANALYSIS BY AGE GROUP |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY COMORBIDITIES |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY COMORBIDITIES |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY COMORBIDITIES |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT |
103. 6.100 REST OF MEA MARKET ANALYSIS BY SEVERITY |
104. 6.101 REST OF MEA MARKET ANALYSIS BY COMORBIDITIES |
105. 6.102 REST OF MEA MARKET ANALYSIS BY AGE GROUP |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TREATMENT, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY SEVERITY, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY SEVERITY, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY COMORBIDITIES, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY COMORBIDITIES, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY AGE GROUP, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY AGE GROUP, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY AGE GROUP, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY AGE GROUP, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY AGE GROUP, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY AGE GROUP, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY AGE GROUP, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY AGE GROUP, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY AGE GROUP, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY AGE GROUP, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY AGE GROUP, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY AGE GROUP, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY AGE GROUP, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY AGE GROUP, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY AGE GROUP, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY AGE GROUP, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY AGE GROUP, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY AGE GROUP, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY AGE GROUP, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY AGE GROUP, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY AGE GROUP, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY AGE GROUP, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY AGE GROUP, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY AGE GROUP, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY AGE GROUP, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY AGE GROUP, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY AGE GROUP, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY SEVERITY, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY AGE GROUP, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Treatment (USD Billion, 2025-2035)

Medications
Psychotherapy
Cognitive Behavioral Therapy (CBT)
Exposure and Response Prevention (ERP)

Healthcare By Severity (USD Billion, 2025-2035)

Mild Panic Disorder
Moderate Panic Disorder
Severe Panic Disorder

Healthcare By Comorbidities (USD Billion, 2025-2035)

Agoraphobia
Social Anxiety Disorder
Generalized Anxiety Disorder
Depression

Healthcare By Age Group (USD Billion, 2025-2035)

Children and Adolescents
Adults
Older Adults

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓